Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBIT: 2022-2025

Historic EBIT for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$43.1 million.

  • Stoke Therapeutics' EBIT fell 43.62% to -$43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 123.18%. This contributed to the annual value of -$101.4 million for FY2024, which is 11.68% up from last year.
  • Latest data reveals that Stoke Therapeutics reported EBIT of -$43.1 million as of Q3 2025, which was down 57.84% from -$27.3 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' EBIT registered a high of $111.2 million during Q1 2025, and its lowest value of -$43.1 million during Q3 2025.
  • Moreover, its 3-year median value for EBIT was -$28.4 million (2024), whereas its average is -$15.9 million.
  • Within the past 5 years, the most significant YoY rise in Stoke Therapeutics' EBIT was 492.08% (2025), while the steepest drop was 43.62% (2025).
  • Quarterly analysis of 4 years shows Stoke Therapeutics' EBIT stood at -$27.2 million in 2022, then declined by 8.87% to -$29.6 million in 2023, then soared by 53.85% to -$13.7 million in 2024, then crashed by 43.62% to -$43.1 million in 2025.
  • Its EBIT was -$43.1 million in Q3 2025, compared to -$27.3 million in Q2 2025 and $111.2 million in Q1 2025.